溶瘤病毒
溶癌病毒
肿瘤微环境
免疫疗法
嵌合抗原受体
免疫系统
免疫检查点
抗原
癌症免疫疗法
癌症研究
免疫学
封锁
病毒
癌症
医学
生物
受体
内科学
作者
Rui Ma,Zhenlong Li,E. Antonio Chiocca,Michael A. Caligiuri,Jianhua Yu
标识
DOI:10.1016/j.trecan.2022.10.003
摘要
Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with cancers resistant to traditional therapies. Natural or genetically modified OVs are multifaceted tumor killers. They directly lyse tumor cells while sparing normal cells, and indirectly potentiate antitumor immunity by releasing antigens and activating inflammatory responses in the tumor microenvironment. However, some limitations, such as limited penetration of OVs into tumors, short persistence, and the host antiviral immune response, are impeding the broad translation of oncolytic virotherapy into the clinic. If these challenges can be overcome, combination therapies, such as OVs plus immune checkpoint blockade (ICB), chimeric antigen receptor (CAR) T cells, or CAR natural killer (NK) cells, may provide powerful therapeutic platforms in the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI